- NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
- Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
- Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
- Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
- CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
- Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
- Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
- Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
More ▼
Key statistics
52-week range
Open | 48.18 |
---|---|
High | 48.55 |
Low | 45.12 |
Bid | 45.30 |
Offer | 48.00 |
Previous close | 47.45 |
Average volume | 1.19m |
---|---|
Shares outstanding | 181.91m |
Free float | 180.09m |
P/E (TTM) | -- |
Market cap | 8.63bn USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼